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Abstract: 
The present study aims to detect CTX-M-type ESBL from Escherichia coli clinical isolates and to 
analyze their antibotic susceptibility patterns. One hundred of E. coli isolates were collected from different 
clinical samples from a tertiary hospital. ESBL positivity was determined by the disk diffusion method. PCR 
used for amplification of CTX-M-type ESBL produced by E. coli. Out of 100 E. coli isolates, twenty-four 
isolates (24%) were ESBL-producers. E. coli isolated from pus was the most frequent clinical specimen that 
produced ESBL (41.66%) followed by urine (34.21%), respiratory (22.23%), and blood (19.05%).  After 
PCR amplification of these 24 isolates, 10 (41.66%) isolates were found to possess CTX-M genes. The CTX-
M type ESBL producing E. coli against antibiotics belonging to different families showed the highest 
resistance rates to Ampicillin (100%), Cefotaxime (97%), Cefuroxime (95%), and Ciprofoxacin (86%). 
Carbapenem groups of antibiotics, Meropenem (89%) and Imipenem (85%) have the highest susceptibility 
rate among all antibiotics used in this study. The outcome of the antimicrobial susceptibility testing of 
significant CTX-M- type ESBL producing E. coli could be useful to avoid failure or prolong treatments.  
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Introduction: 
A heterogeneous enzyme, extended-
spectrum β-lactamase (ESBL) produced by 
Enterobacteriaceae showed resistance to a 
numerous group of antibiotics especially 
Cephalosporins, Penicillins, Monobactams and 
Carbapenems. Among the clinical isolates of 
Enterobacteriaceae, the formation of β-lactamases 
resistance mechanism is very frequent. Infections 
caused by ESBL producing organisms became a 
threat to infection control management and spread 
worldwide.  
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ESBL-producing E. coli is now a serious 
concern in infection control therapies and higher 
prevalence rates in Asia-Pacific countries (1) and 
many parts of the world (2). The prevalence of 
extended-spectrum β-lactamases (ESBL), Metallo 
β-lactamase (MBL) and AmpC producing 
organisms prolong treatment and effective control 
(3). ESBL or MBL associated organisms has an 
effect of higher mortality and morbidity (4). 
In Enterobacteriaceae, resistance mechanisms of 
ESBLs producing CTX-M, TEM, and SHV types 
genes exhibit a major problematic alarming concern 
in various antibiotics (5). The formation of ESBLs 
producing gene (TEM, SHV, and CTX-M) have 
been reported in community and nosocomial 
settings across the world (6).  
The CTX-M-type ESBL gene normally 
hydrolyze third generation antibiotic Cefotaxime 
(CTX) compared to Ceftazidime (CAZ). Moreover, 
the CTX-M type ESBL enzymes are resistant to 
Cefotaxime but persist sensitive to Ceftazidime (6). 
Therefore, these genes are named CTX-M-type 
ESBLs which are highly efficient in genetic 
elements due to the epidemic of plasmids (7). These 
enzymes are either plasmid-mediated or 
chromosomally mediated but commonly on a 
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plasmid in Enterobacteriaceae (2). Plasmid 
mediated CTX-M gene can transfer resistance genes 
to unrelated antimicrobials and within the bacterial 
strains (2, 8). CTX-M type ESBL producing E. coli 
developed co-resistance to various classes of 
antibiotics (9). Ceftazidime (CAZ) normally used to 
detect ESBL producing organisms, but in many 
cases, CAZ alone may not be able to detect CTX-
M-type ESBL producing organisms (10). Till date, 
a various number of different variants of blaCTX-
M-type enzymes has been identified throughout the 
world (10-12). 
This present study aims to look at the 
current scenario of CTX-M-type ESBL 
producing E. coli isolates of different infectious 
specimens from a tertiary hospital, Malaysia using 
phenotypic methods and molecular based 
techniques. 
Materials and Methods: 
Bacterial Isolates 
One hundred E. coli isolates were collected 
at Hospital Selayang, Malaysia from June 2017 to 
June 2018. All the samples were plated on Muller-
Hinton agar plate (Oxoid, Basingstoke, United 
Kingdom) and incubated at 37°C for 24 hours to 
isolates E. coli. All the E. coli isolates were selected 
and reconfirmed by the standard biochemical assay 
described (13, 14). Among these E. coli isolates, 38 
isolates were from urine samples, 21 isolates from 
blood, 13 isolates from stools cultures, 12 isolates 
from pus, 9 isolates from respiratory secretions 
blood cultures, and 7 isolates from sputum samples 
and.  
Antibiotic Susceptibility 
Antibiogram analysis were performed 
among all (100) isolates of E. coli by Kirby Bauer 
disk diffusion method (15) on Mueller-Hinton agar 
in accordance with CLSI (2017) (16). Ten different 
types of antibacterial agents namely Ampicillin (10 
mcg), Amoxicillin/clavulanic acid (20/10 mcg), 
Cefotaxime (30 mcg), Ceftazidime (30 mcg), 
Cefuroxime (30 mcg), Ciprofloxacin (5 mcg), 
Gentamicin (10 mcg), Imipenem (10 mcg), 
Meropenem (10 mcg), and Piperacillin/tazaobactum 
(100/10 mcg) were used in this study. As a 
reference strains for susceptibility confirmation, 
ATCC-25922-E. coli was used in vitro.  
Phenotypic Detection of ESBLs 
Double Disk Synergy Test (DDST) was 
carried out on Muller-Hinton agar plate for the 
detection of ESBLs gene (4, 17). The synergy 
between a third-generation cephalosporins group of 
antibiotics, Cefotaxime 30mg (CTX) and 
Ceftazidime 30mg (CAZ) disk was placed 20mm 
center to center apart from Amoxicillin/clavulanic 
acid (20/10mg) (AMC) disk (17). After the 
overnight incubation, CLSI-2017 guidelines were 
strictly followed for measurement, interpretation, 
and enhancement of inhibition zone indicating 
synergy (an extended zone of inhibition towards the 
Amoxicillin-clavulanic acid) confirms the isolates 
possess ESBL gene (16). ATCC-25922-E. coli 
strains were used as a negative control (13). 
CTX-M Gene Detection Using PCR 
The boiling method was used to extract the 
genomic DNA in our study (18). A pure culture of 
ESBL positive bacterial strains was grown in BHI 
broth at 37°C for 24 hours. After incubation, 200 µl 
broth culture was added to 800 µl of distilled water 
and boiled for 10 minutes at 100°C and then 
centrifuged at 12,000×g for 2 minutes. The 
supernatant containing genome was the DNA 
template for PCR. After amplification, the purified 
DNA was stored at -20°C for further process. The 
targeted CTX-M-type gene detection among the 24 
ESBL positive isolates was confirmed using PCR as 
described (19) with minor modification. Briefly, 
total volume (25 µL/reaction) contained the 
mixtures of 2.5 µL PCR buffer 10X, 1 µL for each 
primer (blaCTX-M-F and blaCTX-M-R), MgCl2 
(25mM) 1.5 µL, 0.5 µL dNTPs (10mM), Taq DNA 
polymerase 0.2 µL, 8.3 µL of water (nuclease-free) 
and 10 µL DNA template. Total 25 µL was used in 
each reaction tube for PCR. The blaCTX primers 
(Table 1) were used according to conditions (Table 
2) for PCR amplification. In agarose gel 
electrophoresis process, 1.5% agarose gel for PCR 
product was stained with ethidium bromide (0.5 
mg/ml) and was run at 100 volts for 35 minutes and 
visualised under UV light. 
 
Table 1. Primers used for detection of blaCTX-
M.  
Genes Primer sequences 
Amplicon 
size (bp) 
References 
blaCT
X-M-F 
ACCGCCGATAAT
TCGCAGAT 
588 (19) 
blaCT
X-M-R 
GATATCGTTGGT
GGTGCCATA 
 
Table 2. PCR conditions to obtain targeted gene. 
Step Temperature Time Cycle 
Initial 
denaturation 
94ºC 5 min 1 
Denaturation 94ºC 1 min 
35 Annealing 59.2ºC 30 sec 
Extension 72ºC 1 min 
Final 
extension 
72ºC 5 min 1 
Storage 4ºC   
 
Statistical Analysis: 
In this present study, the Chi square test was used 
for data analysis. The value of p< 0.05 was 
considered as the significant statistical difference. 
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Results: 
In the present study, disk diffusion synergy 
test and E-test were carried out to confirm ESBL 
production. Among the 100 E. coli isolates only 24 
isolates were found to produce ESBL positive gene 
(Table 3), and the synergism of ESBL isolates was 
observed (Fig. 1).  
 Different types of clinical specimens were 
the sources of E. coli isolates. Among the 12 E. coli 
isolates of pus, 5 (41.66%) isolates were ESBL-
producers while 13 (34.21%) out of 38 E. coli 
isolates of urine were ESBL positive.  None of the 
isolates of stool and sputum were positive for ESBL 
genes. The ESBL production rates among the 
respiratory and blood isolates were 2 (22.23%) and 
4 (19.05%), respectively. These prevalence rates 
were not significant (p> 0.05) between the clinical 
specimen and ESBL-producers (Table 3).  
 
Table 3. ESBL producing clinical isolates. 
Sources / 
specimens 
E. coli 
Total 
(n=100) 
ESBL 
(n=24) 
Non ESBL 
(n= 76) 
 
Urine 
13 
(34.21%) 
25 (65.79%) 38 
Blood 4 (19.05%) 17 (80.95%) 21 
Respiratory 2 (22.23%) 7 (77.77%) 9 
Stool 0 
13 
(100.00%) 
13 
Pus 5 (41.66%) 7 (58.34%) 12 
Sputum 0 7 (100.00%) 7 
Pearson Chi-Square = 10.839 (p = 0.054) 
 
Figure 1. Double disk synergy test with ESBL 
producing E. coli. 
 
 Different types of antibacterial agents showed 
higher resistance rate by E. coli isolates (CTX-M- 
type ESBL) while less resistance in non-ESBL 
isolates. From results, the resistance rates of 
cephalosporins were higher than any other groups 
of antibiotics used. Among the E. coli strains 
(ESBL producers), highest resistance was shown 
towards Ampicillin with the rate of (100%) and 
subsequently Cefotaxime (97%), Cefuroxime 
(95%), Ciprofloxacin (86%), and Ceftazidime 
(72%) (Fig. 2). In non-ESBL producing strains, 
resistance rate was for Ampicillin 78%, Cefotaxime 
67%, Cefuroxime 85%, Ciprofloxacin 66%, and 
Ceftazidime 52%. Surprisingly, Meropenem (11%), 
and Imipenem (15%) showed lower resistance 
among ESBL producing isolates.  
 
Figure 2. Susceptibility of different types of antibiotic among CTX-M-type ESBLs positive E. coli 
isolates. 
 
However, resistance rates are higher in most of the 
E. coli isolates which produce the ESBL gene than 
non-producing ESBL isolates. Out of these 24 
ESBL positive strains, 10 (41.66%) isolates showed 
positive for the blaCTX-M gene, and the rest 14 
(58.34%) isolates did not produce any blaCTX-M 
gene (Fig.3). 
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Figure 3. CTX-M-type ESBL positive E. coli 
isolates after PCR study, M: DNA ladder, Lanes: 
from 1-5 represent amplified product (588 bp) of 
CTX-M positive isolates. 
 
Discussion: 
The higher prevalence rates of ESBL 
producing E. coli due to various resistance 
mechanisms causes hospital-acquired infections. 
We have observed the ESBL phenotype, CTX-M-
type gene and their antibiotics susceptibility 
patterns among the 100 E. coli isolates from a 
tertiary hospital, Malaysia.   
Various ESBLs genes production cause 
outbreaks throughout the world. It is essential to do 
epidemiological identification and molecular 
classification of ESBL genes (20). In the present 
study, 24 isolates were ESBL producer among 100 
clinical isolates of E. coli. The projected prevalence 
rate of E. coli isolates (ESBL producer) ranged 
between 7% and 19% by the Ministry of Health, 
Malaysia (2001) (21) which is in agreement with 
our study. Moreover, a recent study has reported 
that 18.8% of isolates were ESBL producers from 
Hospital Tengku Ampuan Afzan (HTAA) in 2016 
(22). According to the recent studies, the high 
prevalence rates of 56.92% (23), 62.9% (24), 62.8% 
(25), 46.3% (26), 72.3 % (27), 57.7% (28), 91.7% 
(29), and 90.91% (30) ESBL producing isolates was 
observed across the world. Similarly, studies have 
reported the closer prevalence rates of 24% (31), 
25.83% (32), and 26.87 % (33) ESBL producing E. 
coli compared to our study, respectively. However, 
the estimated presence of ESBLs producing E. coli 
should be between 5 to 8% in Asian countries (10). 
Within the past decades, E. coli 
genotype CTX-M has extensively found and spread 
across the world (34).  These enzymes have become 
a severe public health concern causing outbreaks 
throughout the worldwide. Studies have revealed 
that the predominant gene among the β-lactamase is 
CTX-M gene. Currently, the molecular method 
(PCR amplification) is the standard method for the 
detection of ESBL producing (blaTEM, blaSHV, 
and blaCTX-M) gene (10). Our study found that, 
among the 24 ESBL producing E. coli isolates, 10 
(41.66%) were blaCTX-M genes producer (Figure 
3) while 90% isolates were blaCTX-M gene 
producer in 2016 (22). However, we did not test for 
other ESBL producing gene (blaTEM and blaSHV) 
among our clinical isolates. Similarly, various 
prevalence rates of 92.1% (10), 20% (35), and 
11.8% (36) CTX-M gene were observed in 
Malaysia. Moreover, different prevalence rates of 
82.6% (37), 28% (38), 56% (39), 95.2% (40), 
90.6% (26) and 82.5% (23) CTX-M have been 
dominant across the world.  
The highest resistance rates were to 
Cefotaxime (97%) and Cefuroxime (95%) 
respectively while Ceftazidime (72%) among the 
CTX-M-types ESBL isolates. These findings 
support that CAZ alone is not appropriate to 
confirm ESBL productions. Moreover, 
cephalosporin groups of antibiotics showed a higher 
resistance rate in Gram negative bacteria (10, 41). 
This present study revealed that the carbapenems 
groups of antibiotic such as Meropenem (89%) and 
Imipenem (85%) are more susceptible to ESBL-
producing CTX-M-type E. coli compared to 
cephalosporins antibiotics (Cefotaxime 3%, 
Cefuroxime 5%, and Ceftazidime 28%). These 
findings could be important to treat Gram negative 
infections with carbapenems.  
The most prevalent CTX-M type ESBLS 
has become an alarming phenomenon due to their 
unpredictable epidemiological changes in 
antibiotics resistance, allotypic diversity, rapid and 
global spread in Enterobacteriaceae especially 
encountered in E. coli. Some of the possible factors 
such as geographical locations, proficiency level of 
technical staffs, different types of antibiotics usages, 
varied guidelines and techniques might be involved 
in resistance mechanisms across the world. In this 
regards, strict surveillance on antibacterial 
therapeutic agents, emphasise the efficacy of 
molecules, essential laboratory detection and 
overcome the limitation of alternative therapeutic 
management could be possible features to solve or 
decreases the rapid dissemination of CTX-M type 
ESBLs. 
 
Conclusion:  
The higher prevalence rate of ESBL 
producing (CTX-M) E. coli strains has extended 
into a serious level in Malaysia as well as 
worldwide. The molecular classification of CTX-M-
type ESBL producing E. coli isolates may harbour 
multiple ESBL genes too. Our findings recommend, 
an early and regular screening process on clinically 
important isolates demands an extra concern. 
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Reliable monitoring is essential to stop spreading 
ESBLs genes in the local community as well as 
worldwide. Our findings on antibiotic susceptibility 
patterns could be useful for quality assurance, and 
implementation of infectious diseases control 
managements. However, molecular characterization 
of genes requires additional epidemiological 
investigations.  
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رية المعزولة من المستشفى السري  الإشريكية القولونية من M-XTCمن النوع  sLBSEلكشف عن 
 ، ماليزياالثالث
 
 نازمول .م.ح.م   راشد م.ا     نجنين أ    فرزانة .ي    فضل م.ك.ك
 
 :الخلاصة
ولتحليل أنماط  العزلات السريرية الإشريكية القولونية من LBSE M-XTCتهدف هذه الدراسة إلى الكشف عن نوع 
 تم تحديد إيجابية من عينات سريرية مختلفة من المستشفى الثالث.  الإشريكية القولونية للمضادات الحيوية. تم جمع مئة من عزلات حساسيتها
عزلة من  001من بين   الإشريكية القولونية نوع من إنتاج -XTC LBSEتستخدم لتضخيم  RCP .بواسطة طريقة نشر القرص LBSE
المعزولة من القيح أكثر العينات   الإشريكية القولونية كانت .LBSE٪) من منتجي  42الإشريكية القولونية ، كانت أربع وعشرون عزلة (
بعد تضخيم  ٪).50.91، والدم (٪)32.22٪)، والجهاز التنفسي (12.43سبة (٪) متبوعة بالادرار بن66.14( LBSEالسريرية التي أنتجت 
 LBSEمن نوع  M-XTCأظهرت  .M-XTC٪) منها تمتلك جينات  66.14( 01  ، تم العثور على أنعزلة لهذه الاربع والعشرون RCP
 ،٪) 001دلات مقاومة للأمبيسيلين (فة أعلى معمضادة للمضادات الحيوية التي تنتمي إلى عائلات مختل  الإشريكية القولونية الذي ينتج
 98٪). مجموعات الكاربابينيم من المضادات الحيوية، الميروبينيم ( 68، والسيبروفوكساسين (٪) 59٪) ، السيفوروكسيم ( 79يم (السيفوتاكس
يمكن أن تكون نتائج اختبار  .الدراسة٪) لديها أعلى معدل حساسية بين جميع المضادات الحيوية المستخدمة في هذه  58٪) وإيميبينيم (
 مفيدة لتفادي الفشل أو إطالة مدة العلاج. الإشريكية القولونية إنتاج -M-XTCمن نوع  LBSE .Eالحساسية المضادة للميكروبات لـ 
  
 .RCP، الإشريكية القولونية ،  LBSE، جينات M-XTC الكلمات المفتاحية :
 
